Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
Intended for Healthcare Professionals
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
  • Subscribe BJGP on YouTube
Intended for Healthcare Professionals
British Journal of General Practice

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
Clinical Intelligence

Practical guidance on heart failure diagnosis and management in primary care: recent EPCCS recommendations

Clare J Taylor, Frans H Rutten, Judith R Brouwer and FD Richard Hobbs
British Journal of General Practice 2017; 67 (660): 326-327. DOI: https://doi.org/10.3399/bjgp17X691553
Clare J Taylor
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Roles: GP and NIHR academic clinical lecturer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frans H Rutten
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
Roles: Professor of general practice
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith R Brouwer
MEDCON International, Haarlem, the Netherlands.
Roles: Medical scientific writer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FD Richard Hobbs
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Roles: Professor of primary care
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info
  • eLetters
  • PDF
Loading

INTRODUCTION

Heart failure (HF) is a common and costly clinical syndrome, associated with significant morbidity and reduced life expectancy, affecting around 1–2% of adults in developed countries.1 Timely diagnosis is important to optimise evidence-based treatment opportunities, which delay mortality and improve symptoms, but the early stages of HF can be difficult to identify clinically. Primary care has a vital role in providing holistic, person-centred care from first symptoms to end of life. This article summarises the key aspects of HF management for general practice including new areas of diagnostics and drug therapy.

DEFINITION

HF is a clinical syndrome characterised by certain symptoms, and possibly signs, plus objective evidence of a structural or functional abnormality of the heart. The type of HF is determined according to left ventricular ejection fraction (LVEF), although the exact cut-point continues to be an area of debate.2 HF with reduced ejection fraction (HFrEF) is commonly defined as LVEF <40%. HF with preserved ejection fraction (HFpEF) is defined as LVEF ≥50% with evidence of diastolic dysfunction or structural cardiac changes.3 Recently, the European Society of Cardiology (ESC) added a third group, HF with midrange ejection fraction (HFmrEF), for the grey area between HFrEF and HFpEF.3 All three show reduced prognosis compared with the non-HF population. The classification is important for management: HFrEF has a strong evidence base for pharmacological intervention whereas the same treatments have not shown benefit in HFpEF.4

RECOGNISING HEART FAILURE

In both HFrEF and HFpEF, the heart fails to pump adequately, causing symptoms of fluid overload and cardiac stress, such as breathlessness, ankle swelling, and fatigue. These symptoms are common and can be associated with a variety of conditions, not just HF. In addition, patients with HF often have several coexisting conditions, treated with multiple medications, which can complicate the picture further.5 A background of cardiovascular disease, particularly previous myocardial infarction, makes HF more likely. On examination, signs may include crepitations at the lung bases, a raised jugular venous pressure, or a displaced apex beat. Features such as orthopnoea, waking up at night gasping for breath, or a gallop rhythm, are more strongly suggestive of HF, but only occur in severe cases and are less commonly seen in general practice.3,6

INVESTIGATIONS

The National Institute for Health and Care Excellence (NICE) guideline for chronic HF suggests patients with suspected HF should be further investigated initially with natriuretic peptide (NP) testing, except if there is a history of myocardial infarction, where referral directly to echocardiography is advised.6 NP thresholds need to be low enough to rule out HF. NICE recommends that below N-terminal pro B type NP (NT-proBNP) 400 pg/mL, and B type NP (BNP) 100 pg/mL, HF is unlikely and to consider alternative diagnoses. However, several factors need to be taken into account when interpreting results: renal impairment and atrial fibrillation (AF) can increase NP levels; and in overweight patients and users of diuretics or angiotensin-converting enzyme inhibitors (ACE-I) NP may be reduced. If a patient has NP levels above cut-off values, echocardiography and review by a cardiologist are required to confirm the diagnosis.

The NICE NP thresholds are higher than the levels suggested by the ESC HF guidelines,7 which recommend further investigation at NT-proBNP above 125 pg/ml rather than 400 pg/ml. Furthermore, the recent REFER trial dataset based in UK general practice confirmed 125 pg/ml as a safer threshold because 400 pg/ml excluded 20% of people who had HF.2

Additional blood tests to rule out precipitating factors such as thyroid disease or anaemia, measure modifiable cardiovascular risk factors, and assess baseline liver and renal function prior to initiating treatment are also important. Electrocardiogram (ECG) is useful to detect possible causes, and consequences, of HF, such as AF. Chest X-ray can be normal, except in the case of clear fluid overload, but may identify another cause for the breathlessness. Echocardiography is used to determine the type of heart failure and other structural or functional abnormalities, such as valvular heart disease. HFrEF is, as the name suggests, characterised by a reduced ejection fraction whereas in HFpEF ejection fraction is normal but other abnormalities, such as increased left ventricular stiffness and a restrictive left ventricular filling pattern, are evident.8

HOLISTIC MANAGEMENT

Patients with HF usually have several other comorbidities, often requiring multiple medications; HF may not be their main burden. A patient-centred approach, coordinated by a generalist, may therefore be most appropriate over the long term. But specialist expertise in HF will be required at diagnosis and at intermittent points throughout the patient’s healthcare journey. Hospital and community-based HF nurses can play an important role in providing continuity.

Patients with HF should understand their condition and be actively involved in management decisions. It is also important to encourage aspects of self-care. Lifestyle interventions can improve patients’ quality of life and prevent exacerbations. Patients should be made aware of the role of salt and encouraged to avoid overuse, the importance of ensuring adequate hydration and a healthy diet, and the benefits of regular exercise in increasing their functional capacity. Patients with HF also benefit from formalised rehabilitation programmes that combine exercise with lifestyle and educational components, as well as psychological support.3,6 End-of-life care is also an important but challenging part of HF management. There is significant individual variation in the disease trajectory of HF and patients generally do not follow a gradual downward path. Some feel and function quite well and die suddenly, whereas others may improve after a period of poor health. In the context of multimorbidity, HF may not be the final mode of death.5

DRUG TREATMENT — OLD AND NEW

Diuretics are vital in the initial phase of treatment to offload fluid and improve symptoms in patients with all types of HF. Their use though is empirical and trial evidence does not (and will not) exist. ACE-I, beta-blockers (BB), and mineralocorticoid receptor antagonists (MRA) have been shown to significantly improve survival and quality of life, and to reduce hospital admissions in patients with HFrEF. The same effects were not seen in trials of HFpEF patients.4

Ivabradine may benefit patients in sinus rhythm with a LVEF <35% and heart rate at or above 70 bpm who remain symptomatic after ACE-I, BB, and MRA treatment. Device therapies, such as cardiac resynchronisation (QRS), in patients with LVEF <35% and QRS duration >130 ms on ECG might also improve cardiac function. Digoxin was one of the first drugs to be used in HF, although outcomes of trials have shown only modest benefit. Patients with HF and in sinus rhythm on digoxin had fewer hospitalisations but no overall decrease in mortality. Digoxin may be of use in patients with HF and AF to control ventricular rate.

The participants of HF trials were traditionally younger, male, and with less comorbidity than today’s general practice population, so the presence of comorbidities, particularly chronic kidney disease, may limit optimisation of drug therapy. A patient-centred approach, balancing symptom improvement and prognostic benefit through shared decision making, is required to provide the most appropriate care.

A new class of drug has recently been introduced to HF management options. Angiotensin receptor neprilysin inhibitors, or ARNIs, exert a dual action through inhibition of the renin–angiotensin system and potentiation of protective vasoactive neuropeptides. The first ARNI to be licensed is sacubitril-valsartan and was evaluated in the PARADIGM-HF trial.9 Symptomatic patients with LVEF <40% on optimal background HF therapy (such as diuretics, ACE-I, BB, and MRAs) were recruited and randomised to sacubitril-valsartan or enalapril 20 mg twice daily. The trial was stopped early due to significantly reduced cardiovascular mortality and hospitalisation in the ARNI group. Sacubitril-valsartan has been approved by NICE for use in the NHS but may only be initiated by specialists.

CONCLUSION

General practice plays a key role in recognising, investigating, referring, and managing patients with HF. Generalists and specialists together should provide person-centred care that optimises both the quantity and quality of life. The European Primary Care Cardiovascular Society has produced detailed practical guidance on heart failure diagnosis and management, available at epccs.eu.

Notes

Provenance

Freely submitted; externally peer reviewed.

Competing interests

The authors have declared no competing interests.

Discuss this article

Contribute and read comments about this article: bjgp.org/letters

  • Received October 10, 2016.
  • Revision requested October 26, 2016.
  • Accepted December 21, 2016.
  • © British Journal of General Practice 2017

REFERENCES

  1. 1.↵
    1. Roger VL
    (2013) Epidemiology of heart failure. Circ Res 113(6):646–659.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Taylor CJ,
    2. Roalfe AK,
    3. Iles R,
    4. et al.
    (2017) Primary care REFerral for EchocaRdiogram (REFER) in heart failure: diagnostic accuracy study. Br J Gen Pract, DOI: https://doi.org/10.3399/bjgp16X688393.
  3. 3.↵
    1. Ponikowski P,
    2. Voors AA,
    3. Anker SD,
    4. et al.
    (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Paulus WJ,
    2. van Ballegoij JJ
    (2010) Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 55(6):526–537.
    OpenUrlFREE Full Text
  5. 5.↵
    1. Barnett K,
    2. Mercer SW,
    3. Norbury M,
    4. et al.
    (2012) Epidemiology of multimorbidity and implications for healthcare, research, and medical education: a cross-sectional study. Lancet 380(9836):37–43.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. National Institute for Health and Clinical Excellence
    (2010) Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. CG108 (NICE, London) http://www.wales.nhs.uk/sitesplus/documents/861/NICE%20Guidelines%20-%20Chronic%20Heart%20Failure.pdf (accessed 17 May 2017).
  7. 7.↵
    1. Ponikowski P,
    2. Voors AA,
    3. Anker SD,
    4. et al.
    (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200, https://academic.oup.com/eurheartj/article/37/27/2129/1748921/2016-ESC-Guidelines-for-the-diagnosis-and (accessed 9 Jun 2017).
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Penicka M,
    2. Vanderheyden M,
    3. Bartunek J
    (2014) Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography. Heart 100(1):68–76.
    OpenUrlFREE Full Text
  9. 9.↵
    1. McMurray JJ,
    2. Packer M,
    3. Desai AS,
    4. et al.
    (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004.
    OpenUrlCrossRefPubMed
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 67 (660)
British Journal of General Practice
Vol. 67, Issue 660
July 2017
  • Table of Contents
  • Index by author
Download PDF
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Practical guidance on heart failure diagnosis and management in primary care: recent EPCCS recommendations
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Practical guidance on heart failure diagnosis and management in primary care: recent EPCCS recommendations
Clare J Taylor, Frans H Rutten, Judith R Brouwer, FD Richard Hobbs
British Journal of General Practice 2017; 67 (660): 326-327. DOI: 10.3399/bjgp17X691553

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Practical guidance on heart failure diagnosis and management in primary care: recent EPCCS recommendations
Clare J Taylor, Frans H Rutten, Judith R Brouwer, FD Richard Hobbs
British Journal of General Practice 2017; 67 (660): 326-327. DOI: 10.3399/bjgp17X691553
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • INTRODUCTION
    • DEFINITION
    • RECOGNISING HEART FAILURE
    • INVESTIGATIONS
    • HOLISTIC MANAGEMENT
    • DRUG TREATMENT — OLD AND NEW
    • CONCLUSION
    • Notes
    • REFERENCES
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • How to manage low testosterone level in men: a guide for primary care
  • Hyperparathyroidism (primary) NICE guideline: diagnosis, assessment, and initial management
  • The atypical presentation of COVID-19 as gastrointestinal disease: key points for primary care
Show more Clinical Intelligence

Related Articles

Cited By...

Intended for Healthcare Professionals

BJGP Life

BJGP Open

 

@BJGPjournal's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2023 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242